Codexis vs Protalix BioTherapeutics
CDXS and PLX side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CDXS and PLX compare
Protalix BioTherapeutics is the larger company, worth 1.9 times as much as Codexis ($246M against $127M).
Codexis grew revenue faster over the last twelve months (66.9% versus 37.0% for Protalix BioTherapeutics).
Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 24.3% compared with −21.8% at Codexis.
Protalix BioTherapeutics scores higher on the StockData Score (16 against 5 for Codexis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CDXS | PLX |
|---|---|---|
| Size and price | ||
| Market cap | $127M | $246M |
| Share price | $1.16 | $3.05 |
| Change, 1 year | −39.9% | 42.5% |
| Change, 5 years | −96.9% | 211% |
| Beta (5Y) | 2.42 | 0.87 |
| Employees | 146 | 226 |
| StockData Score | ||
| Total score | 5 | 16 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 12.2× |
| P/S | 1.4× (better) | 2.9× |
| P/B | 2.5× (better) | 3.1× |
| EV/EBITDA | – | 8.9× |
| P/FCF | – | 16.3× |
| FCF yield | −9.6% | 6.1% (better) |
| Fair value | $1.42 | $6.09 |
| Margin of safety | 18.3% | 49.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 66.9% (better) | 37.0% |
| Revenue growth, 5Y average | 0.38% (better) | −3.5% |
| Net income growth (TTM) | – | 281% |
| EPS growth (TTM) | – | 525% |
| Profitability | ||
| Gross margin | 86.8% (better) | 71.2% |
| Operating margin | −18.3% | 29.8% (better) |
| Net margin | −21.8% | 24.3% (better) |
| FCF margin | −13.7% | 17.8% (better) |
| Return on equity | −42.9% | 30.8% (better) |
| Return on invested capital | −64.7% | 41.0% (better) |
| Financial health | ||
| Debt / equity | 0.81 (better) | 0.00 |
| Current ratio | 2.81 | 3.27 (better) |
| Altman Z-score | −4.59 | 6.03 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 63.7% | 17.9% |
| Held by insiders | 2.2% | 3.8% |
| Insider net buying, 12 months | −$899K | $101K (better) |
| Short interest, % of float | 4.1% | 4.5% |
Go deeper
- CDXS stock overview
- CDXS income statement
- CDXS valuation and score
- PLX stock overview
- PLX income statement
- PLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.